Articles tagged "FK506"

2021 American Transplant Congress
Ectopic Hepatocyte Transplantation Into the Lymph Nodes in a Fully Mismatched Allogeneic Dog Model Using Tacrolimus and Prednisone
P. A. Fontes
NA, LyGenesis, Pittsburgh, PA
*Purpose: Develop organogenesis through ectopic hepatocyte transplantation (HT) into the upper abdominal lymph nodes (LN).*Methods: Three groups of Mongrel dogs weighting between 25-35 kg (control…
2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, K. Lim, M. Gillespie, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…
2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
J. D. Momper¹, S. J. Patel², M. A. Moten², D. R. Stevens², U. Meier-Kriesche²
¹Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, ²Medical Affairs, Veloxis Pharmaceuticals, Cary, NC
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…
2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
K. S. Walter¹, T. Wert¹, R. Coakley², L. J. Lobo², R. A. Evans¹
¹Department of Pharmacy, University of North Carolina, Chapel Hill, NC, ²Department of Medicine, University of North Carolina, Chapel Hill, NC
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…
2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
R. Winstead¹, D. Kumar¹, A. Brown¹, I. Yakubu¹, C. Song¹, L. Thacker², G. Gupta¹
¹Virginia Commonwealth University Health, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…
2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
D. Xu¹, K. Richards¹, K. Zheng¹, H. Patel², F. Cardarelli², J. A. Pena³, A. Aala²
¹Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ³Pathology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…
2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
A. Demirag¹, P. L. Lobo², J. Oberholzer¹, A. Kumar², B. Rawashdeh¹, S. L. Lennon¹, H. N. Guvener Demirag¹, A. Doyle², J. Geystone³, K. L. Brayman¹
¹Transplantation, University of Virginia Medical Center, Charlottesville, VA, ²Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, ³Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
2020 American Transplant Congress
Imaging OX40+Alloreactive T Cells Provides Early Warning of Organ Transplant Rejection
T. Hirai¹, A. Mayer², T. W. Nobashi², Z. Xiao², T. Udagawa³, K. Seo⁴, F. Simonetta⁵, J. Baker⁵, A. Cheng³, S. S. Gambhir², R. S. Negrin⁵
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Radiology, Stanford University, Stanford, CA, ³Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, ⁴Division of Cardiovascular Medicine, Stanford University, Stanford, CA, ⁵Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA
*Purpose: Diagnosis of organ transplant rejection relies upon biopsy approaches to confirm alloreactive T cell infiltration in the graft. Immuno positron emission tomography (immunoPET) utilizing…
2020 American Transplant Congress
Trust and Transparency in Artificial Intelligence-Aided Immunosuppression Decisions
J. Clement
Information and Decision Sciences, University of Minnesota, Minneapolis, MN
*Purpose: In transplant, there is significant interest in using Artificial Intelligence (including machine learning or predictive models) Clinical Decision Support Systems(AI CDSS). Properly designing and…
2020 American Transplant Congress
Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
D. Nnani¹, A. Campbell¹, M. Ajaimy², S. R. Patel³, O. Saeed³, D. J. Goldstein⁴, J. Graham⁵, U. P. Jorde³
¹Pharmacy, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, ⁴Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, ⁵Surgery, Montefiore Medical Center, Bronx, NY
*Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…